Compliance Status
Halal
Screened on Oct 17, 2026 · AAOIFI Standard 21
Good
Is Supernus Pharmaceuticals, Inc. (SUPN) halal? Halal. Based on AAOIFI screening, Supernus Pharmaceuticals, Inc. passes both qualitative (business activity) and quantitative (financial ratio) screens with a compliance score of 75/100 (Grade: B+).
Quote this verdict
HalalScreener rates Supernus Pharmaceuticals, Inc. (SUPN) Halal, 75/100, grade B+ under AAOIFI Standard 21, screened Oct 17, 2026. Source: https://halalscreener.app/en/stock/SUPN
Business activity
What the company sells is permissible.
Company debt
Well clear of the limitHow much the company borrows, compared to its total value. AAOIFI allows up to 30%.
The verdict above is final and free.
Pro members can verify every number behind it: interest-bearing deposits, prohibited income breakdown, and the full AAOIFI math.
Screened according to AAOIFI Standard 21
What this means for you
You can own SUPN
It passes both the business activity and financial ratio screens under AAOIFI Standard 21.
Purification amount is Pro
We have screened SUPN's prohibited income, but the exact share you would need to purify is part of Pro.
SUPN: Is Supernus Pharmaceuticals, Inc. Halal?
Supernus Pharmaceuticals, Inc.
$37.88
Market Cap: 2.2B
Get an email if SUPN's halal status changes
We re-screen Supernus Pharmaceuticals, Inc. daily. If the verdict moves, you hear about it the same day.
Free. One click sets it up, and you can unsubscribe any time.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
Sector: Healthcare · Industry: Drug Manufacturers - Specialty & Generic
Shariah Compliance Status
Want to check the math yourself?
The verdict above is final and free. Pro members can verify every ratio behind it: interest-bearing deposits, prohibited income breakdown, and the full math.
AI Compliance Insight
PROInstitutional-grade Shariah analysis
See why SUPN is rated Halal with institutional-grade analysis
The verdict above is final and free.
Pro members can verify every number behind it: interest-bearing deposits, prohibited income breakdown, and the full AAOIFI math.
Screened according to AAOIFI Standard 21
Compliance History
Halalnow
since Jun 2026
Not Halal
until the change above
Halal
until the change above
Tracked since May 2026. Updates automatically on each re-screen.
More Healthcare Stocks
Know the day SUPN's verdict changes
A free account keeps watch on 3 stocks and emails you when a verdict moves. You also get 3 questions for the AI Scholar. No card needed.
Frequently Asked Questions
Is Supernus Pharmaceuticals, Inc. (SUPN) halal to invest in?
Why did Supernus Pharmaceuticals, Inc. get a B+ compliance rating?
What could change Supernus Pharmaceuticals, Inc.'s Shariah verdict?
How often is Supernus Pharmaceuticals, Inc. re-screened for Shariah compliance?
Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.
Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.